Compare General Dynamics Corporation (GD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Summit Therapeutics Inc — how do they compare? General Dynamics Corporation trades at $392 (market cap $106.03B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: General Dynamics Corporation is far larger — about 8.8× Summit Therapeutics Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GD | SMMT | |
|---|---|---|
Market Cap | $106.03B | $12.06B |
Sector | Industrials | Health |
52-Week High | $395.97 | $26.98 |
52-Week Low | $312.53 | $12.55 |
Enterprise Value | $111.17B | $11.39B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $394.17, down 0.45% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating estimates, revenue growth to $52.55B in 2025, and improving profit margins. Recent contract wins include a $29.5B submarine award and a $1.3B Army cybersecurity contract, supporting the $136.5B backlog.
Outlook remains positive with analyst consensus target of $427.40 representing 8.4% upside potential. Key opportunities include defense budget tailwinds and strong contract pipeline, while risks involve valuation concerns at 23.9 P/E and execution challenges on large government contracts. The stock offers steady dividend payments with recent $1.59 quarterly declaration.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
